STANDARD BIOTOOLS INC. — Director's Dealing 2011

Feb 9, 2011

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: FLUIDIGM CORP (FLDM)
CIK: 0001162194
Period of Report: 2011-02-09

Reporting Person: Loh Jeremy (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series E Preferred Warrant (Right to Buy)	$24.22		Common Stock (43853)		Indirect
Series E Preferred Stock	$0		Common Stock (1047955)		Indirect
Series D Preferred Stock	$0		Common Stock (623531)		Indirect
Series C Preferred Stock	$0		Common Stock (128025)		Indirect
Stock Option (Right to Buy)	$8.38		Common Stock (8670)		Direct

Footnotes

F1: Reflects the automatic conversion of each share of Series E Preferred Stock into 1.3 shares of Common Stock to occur upon the closing of the Issuer's initial public offering.

F2: Expires immediately prior to the closing of the Issuer's initial public offering.

F3: Biomedical Sciences Investment Fund Pte ltd is the record holder of the securities reported on Lines 1, 2 and 3 of Table II.

F4: EDB Investments Pte Ltd, or EDB Investments, is the parent entity of Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. The Economic Development Board of Singapore, or EDB, is the parent entity of EDB Investments. EDB is a Singapore government entity. EDB Investments, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the shares owned beneficially and of record by Biomedical Sciences Investment Fund Pte Ltd and Singapore Bio-Innovations Pte Ltd. Jeremy Loh, the reporting person, is a member of the Issuer's Board of Directors and a Vice President (Investments), San Francisco Center for EDB Investments Pte Ltd, Singapore. Dr. Loh disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F5: Reflects a 1-for-1.73 reverse stock split of the Issuer's outstanding shares effected on February 3, 2011 (Commission File No. 333-170965).

F6: Each share has no expiration date.

F7: Reflects the automatic conversion of each share of Series C Preferred Stock and Series D Preferred Stock into one share of Common Stock to occur upon the closing of the Issuer's initial public offering. Each share has no expiration date.

F8: Singapore Bio-Innovations Pte Ltd is the record holder of the securities reported on Line 4 of Table II.

F9: 1/12th of the shares subject to such Option shall vest on each monthly anniversary of November 30, 2010 (the "Vesting Commencement Date"), such that the Option will be fully vested on the first annual anniversary of the Vesting Commencement Date. The Option shall expire on January 6, 2021.